"We are delighted to announce today's completion of this important milestone. This will enable us to access the largest economic area of our target markets. The experience of granting the patent in Europe provided important insights into the allocation process in the US. This meant that the project duration could be shortened considerably, "says Anke Rauterkus, CEO of Resaphene Suisse AG.
Resaphene Suisse AG: US Patent Office Announces Patent for Tinnitus Therapy tinniwell (news with additional features)
"We are delighted to announce today's completion of this important milestone. This will enable us to access the largest economic area of our target markets. The experience of granting the patent in Europe provided important insights into the allocation process in the US. This meant that the project duration could be shortened considerably, "says Anke Rauterkus, CEO of Resaphene Suisse AG.